ASCO (American Society of Clinical Oncology) shared on X:
“Breaking research on GLP-1s and cancer from ASCO 2025: For people with obesity and diabetes, GLP-1 receptor agonists are associated with a modestly lower risk of obesity-related cancers, especially colorectal cancer.”